诺华从Voyager获得基因治疗组件许可

2024-09-05 21:16

Voyager Therapeutics (NASDAQ:VYGR) announced Thursday that Novartis (NYSE:NVS) has agreed to license a gene therapy component called capsid generated from its TRACER capsid discovery platform as part of its 2022 collaboration with the Swiss drugmaker.
Voyager (VYGR), whose lead asset VY-TAU01 is an Alzheimer's candidate, said Novartis (OTCPK:NVSEF) has licensed the capsid for use in a gene therapy program against an undisclosed rare neurologic disease target.
In exchange, the company is set to receive $15M upfront, milestone payments worth $305M, and mid-to high-single-digit royalties on product sales.
Under its license option agreement with Novartis (OTCPK:NVSEF), Voyager (VYGR) was set to receive potential option exercise fees and milestone payments worth up to $1.7B.
The partnership has extended to five gene therapy programs, from Huntington's disease to spinal muscular atrophy.

More on Novartis, Novartis AG, etc.